The evidence synthesis for this review involved a comprehensive evaluation of the available literature on the impact of SGLT2 inhibitors on serum magnesium levels in patients with type 2 diabetes mellitus (T2DM) and other conditions associated with hypomagnesemia. Here, SLC5A2 is linked to diabetes mellitus.